drugset
drugset / Trial / NCT05016284

Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis

NCT05016284 ↗

Phase 3 Withdrawn Applied Biology, Inc. Jupiter Wellness, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

To compare the efficacy of a JW-100 cream with active control (commercially available as EUCRISA®, Pfizer) for the treatment of atopic dermatitis (AD) in adult patients with mild to moderate AD measured with the Investigator's Static Global Assessment (ISGA) scale.

Timeline

Start
2022-11-24
Primary completion
2022-12-15
Completion
2022-12-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Crisaborole Small molecule — Topical

Indications

atopic eczema